The circulating levels of antiangiogenic molecules such as soluble fms-like tyrosine kinase receptor 1 (sFLT1) and soluble endoglin have been shown to be significantly elevated in pre-eclampsia patients prior to the appearance of symptoms.
Placenta is an important source of sFLT1 molecule during pregnancy, and most of the sFLT1 immunoreactivity in human placentas has been shown to be associated with syncytiotrophoblast cells. 3 Serum levels of sFLT1 start to decline immediately after delivery supporting its placental origin. An alternative splicing of FLT1 mRNA comprising of the extracellular domain of FLT1 produces sFLT1. 4 Placental growth factor (PLGF) and vascular endothelial growth factor (VEGF), two important factors necessary for successful pregnancy, utilize FLT1 as receptor. 5, 6 Circulating sFLT1 antagonizes PLGF and VEGF by preventing their binding to FLT1 and thus interfering with their biological functions. 7 Several isoforms of sFLT1
(145Kd, 100Kd, and 60Kd) in placenta and maternal plasma have been identified recently and shown to be elevated in pre-eclampsia patients. 8 Semi-allogenic nature of fetus is long speculated to be an immunological challenge to the maternal immune system. Therefore, impaired maternal immune tolerance of the fetus has been proposed as a major trigger for many pregnancy-associated diseases including pre-eclampsia. 9 Systemic levels of complement activation products were higher in pregnant women compared to non-pregnant women which were further elevated in the circulation of pre-eclampsia patients. 10 More importantly, the levels of these complement split products were elevated in the maternal circulation preceding the clinical disease indicating a causal relation to pre-eclampsia. 11, 12 In addition, higher amounts of complement split product C4d were found to be deposited on placentas from pre-eclampsia patients compared to those from normal pregnancy, 13 suggesting that placenta may be the origin for elevated systemic split products of complement activation found in pre-eclampsia patients.
The complement cascade consists of more than 30 again attached to cell surface binds to serum proteins C6, C7, and C8 to form a membrane pore like complex. This complex is then reinforced by the insertion of one or more C9 molecules resulting in the generation of final product, the membrane attack complex (MAC).
The split products C3a and C5a are released in to circulation. These products are anaphylatoxins capable of exerting biological functions through their receptors in various types of cells. Insertion of MAC in to cell membrane results in cell lysis due to its hydrophilic pore.
However, nucleated eukaryotic cells resist MAC-mediated lysis to variable extent by actively removing MAC lesions from their surface.
But sublethal levels of MAC have been shown to activate a variety of signaling pathways in several cell types.
Although it is well known that pregnancy is associated with elevated systemic complement activation products originated in placenta and they are further elevated in pre-eclampsia patients, the effect of complement activation on human trophoblast cells in terms of generating antiangiogenic milieu is not well understood. In this study using human trophoblast cells isolated from placentas of normotensive pregnancies, we show that in vitro complement activation upregulated sFLT1 mRNA. Further, we also show that complement activation induced the secretion of sFLT1 in a manner dependent on the degree of activation and the secretion of sFLT1 was correlated with shedding of MAC from these cells.
| ME THODS

| Human placentas
Term placentas were obtained from five normotensive pregnant women immediately after scheduled cesarean deliveries at Baylor
College of Medicine and University of Texas Medical Branch. The study protocol was approved by Institutional Review Boards.
Informed consent was obtained from the patients before placenta collection. Placentas were transferred sterile to the laboratory in saline and immediately washed thoroughly to remove blood. Villi were carefully scraped out to remove them from accompanying vessels and connective tissue, rinsed with saline and then minced in HBSS for trophoblast cell isolation. For proximity ligation assay (PLA), villous tissue was frozen in optimum cutting temperature (OCT) blocks and later thin sections (5 μm) were made using a cryotome.
| Trophoblast cell isolation
Trophoblast cells from term placentas were isolated as described earlier. 14, 15 Briefly, every 50 g wet tissue was digested with trypsin (2.5%) in HBSS containing HEPES for 20 minutes at 37°C with gentle and constant stirring in a total volume of 150 mL. DNAse (1.2 mL of 10×) was then added and the incubation was continued for another 10 minutes. The extract free of debris was then passed through a cell strainer and collected in FBS containing tubes. The remaining tissues were then digested two more times and similarly collected in FBS containing tubes. These tubes were centrifuged for 6 minutes at 1200 g. Pellets were re-suspended while the supernatants were discarded. The suspended pellet was then layered on top of 60%-30% Percoll gradient and centrifuged for 20 minutes at 1200 g. The middle portion of the gradient containing trophoblast cells was then carefully removed, washed in DMEM. Cells were then counted and plated in 6-well cell culture
plates with a density of 1.5 million cells/plate in DMEM containing 10% FBS at 37°C, 5% CO 2 , and 95% air. After 72 hours, syncytialization was checked by examining the production of human chorionic gonadotropin. 
| Complement activation
| Immunoassays
sFLT1 was quantified using VEGFR1 ELISA kit (Reddot Biotech, Kelowna, BC, Canada). MAC quantification was performed using MAC ELISA kit (MyBiosource, San Diego, CA, USA).
| RT-qPCR
FLT1 mRNA levels were measured by qRT-PCR using SYBR green (BioRad, Hercules, CA, USA) as described earlier. 16 Total RNA was isolated from trophoblast cells using the RNAeasy mini kit. cDNA was synthesized using SuperScript III one step RT-PCR system with platinum Taq DNA polymerase (Life Technologies, Walthum, MA, USA). The primer sequences used were forward 5′-TTGGGACTGTGGGAAGAAAC-3′
and reverse 5′-TTGGAGATCCGAGAGAAAACA-3′. β-actin was used as internal control.
| Western analysis
Cell lysates containing 10 μg protein were electrophoresed on 5%-20% (w/v) polyacrylamide gradient gels (Novex, Life Technologies) and transferred on to Immune-Blot PVDF Membranes (Bio-Rad).
Expression of sFLT1 was probed with goat polyclonal human anti- 
| Proximity ligation assay
Proximity ligation assay was performed according to the instructions provided by the manufacturer (Olink Biosciences, Uppsala, Sweden).
Briefly, villous tissue sections were incubated with primary antibodies for goat polyclonal human anti-C9 and Rabbit Anti-Human objective. Images were processed and red spots were counted using Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA).
| Statistical analysis
The data are presented as mean ± SEM. Data obtained from paired experiments where cells isolated from same placenta were treated with different zymosan or anti-HLAG antibody concentrations were analyzed using Wilcoxon's test. Data from triplicate experiments for more than two groups were analyzed by ANOVA followed by Tukey's multiple comparison tests. Student t test was used when two groups were compared followed by Mann-Whitney test. A P value of less than 0.05 was considered to be significant.
| RE SULTS
| Complement activation upregulates sFLT1 levels in human syncytial trophoblast cells
Isolated trophoblast cells were cultured for 72 hours to undergo spontaneous syncytialization. An average of 94% purity was obtained for trophoblast cells with the current isolation method as assessed by counting cytokeratin-7 positive cells ( Figure 1A ).
We used 10% pooled normal human serum (NHS) as source of complement proteins because at this dilution, the complement activation generated non-lethal doses of MAC on human neutrophils. 17 We used zymosan which is a commonly used yeast cell wall derivative to trigger the complement activation via all three pathways of complement cascade. [18] [19] [20] Initially, we optimized the zymosan concentrations to attain sublethal levels of complement activation at different degrees. Deposition and release of MAC as assessed by immunostaining and ELISA, respectively, confirmed that 0.01%, 0.1%, and 0.5% zymosan in culture media activated complement to different degrees ( Figure 1B-D) . We then examined cytotoxicity of complement activation at these levels on syncytiotrophoblast cells by LDH release assay ( Figure 1E ).
The % cytotoxicity was 0.79 ± 0.06, 1.82 ± 1.05, and 3.98 ± 1.67 upon complement activation using 0.01%, 0.1%, and 0.5% zymosan, respectively, indicating that complement activation was sublethal.
To test the effect of complement activation on expression of sFLT1, mRNA levels were measured by RT-qPCR at 24 hours.
Complement activation using 0.01% zymosan significantly increased sFLT1 mRNA levels (2 ± 0.09-fold, P = 0.028) compared to NHS alone without zymosan and C3/C4 depleted NHS with 0.01% zymosan control groups (Figure 2A ). At protein level, expression of all three isoforms of sFLT1 (145Kd, 100Kd, and 60Kd) increased upon complement activation using 0.01% zymosan compared to zymosan negative and NHS negative control groups 
| Complement activation induced secretion of sFLT1
As degree of complement activation depends on concentrations of effector and regulator proteins and their structure-function status, we sought to test the effect of degree of complement activation on sFLT1 protein levels in trophoblast cells. Western blot analysis of cell lysates ( Figure 3A ) followed by protein band density analysis showed that complement activation with all three concentrations of zymosan significantly increased 100 Kd sFLT1 protein levels in these cells This led us to hypothesize that complement activation induced release of sFLT1 protein depending on the degree of activation.
To test this hypothesis, sFLT1 levels in cell culture media were measured by ELISA ( Figure 3C ). Complement activation with all three concentrations of zymosan significantly increased sFLT1
protein levels in culture media compared to no complement activation (0.21 ± 0.03, 1.12 ± 0.62, 1.7 ± 0.68 and 2.69 ± 1.2 ng/mL with 0%, 0.01%, 0.1% and 0.5% zymosan respectively, P = 0.015). optimized antibody dose at sub-saturation levels ( Figure 4A ) to attain MAC levels similar to that obtained by zymosan ( Figure 4B ).
RT-qPCR of sFLT1 mRNA ( Figure 4C ) reveled that complement activation triggered by antibody pre-sensitization significantly upregulated sFLT1 expression (1.3 ± 0.02-fold, P = 0.028). ELISA of sFLT1 ( Figure 4D ) further showed that complement triggered by antibody pre-sensitization induced the release of sFLT1 in to culture media in a manner dependent on degree of activation (0.12 ± 0.01, 0.79 ± 0.04 and 1.5 ± 0.02 ng/mL with 0, 2.5 and 5 μg antibodies respectively, P = 0.007).
| Higher levels of MAC deposited on placentas from pre-eclampsia patients
To test if complement activation is increased on placenta in preeclampsia patients we compared MAC levels on placentas from preeclampsia and normotensive pregnancies by performing PLA. As C9 is part of MAC complex, we used anti-C9 antibody and anti-MAC antibody that recognizes a neoepitope present only in the full MAC complex. Therefore, each fluorescent dot on the tissue represents a single MAC complex. The comparison between two groups was made by normalizing the number of dots in microscopic area to number of nuclei and expressed as dots/nucleus. The PLA ( Figure 5A ) followed by quantification of dots per nucleus revealed ( Figure 5B ) that significantly higher levels of MAC were deposited on placentas from preeclampsia patients compared to those from normotensive pregnancies (2.26 ± 0.92 and 0.59 ± 0.16 dots/nucleus respectively, P = 0.03).
| C3a induced upregulation but not the release of sFLT1
We partially addressed which components of complement cascade are involved in the sFLT1 upregulation and release.
To this end, we tested 
| D ISCUSS I ON
To our knowledge, this is the first report of a direct effect of comple- ternal circulation prior to the onset of pre-eclampsia symptoms. 21, 22 Mechanistically, sFLT1 has been shown to dysregulate TGF-β and nitric oxide signaling and thus affect the vascular functions responsible for maternal symptoms of pre-eclampsia. 23 Now it is well accepted that placenta is the major source of sFLT1 24 and delivery of placenta leads to immediate decrease in serum sFLT1 levels. 21 We have shown that both zymosan and antibody pre-sensitization-mediated complement activation induced upregulation and release of sFLT1 in syncytiotrophoblast cells. Zymosan activates classical pathway in culture medium via antigen-antibody complex formation due to the presence of natural antibodies against zymosan in NHS. This is similar to complement activation by autoantibodies and thus could explain increased frequency of pre-eclampsia in women with autoimmune diseases such as antiphospholipid syndrome. Because of its semiallogenic nature, placenta could trigger an immune response from the maternal system and in fact it has been shown that complement activation products such as C3a and C5a were elevated in the maternal circulation in pregnant women compared to non-pregnant women. 25 Complement activation in normal pregnancy may be due to the direct contact of syncytiotrophoblast cells with maternal blood and thus exposure of paternal antigens to the maternal complement. Antibody pre-sensitization mimics exposure of paternal antigens to maternal blood and subsequent formation of antigen-antibody complexes and thus could explain complement activation on syncytiotrophoblast cells in normal pregnancy. However, normal pregnancy appears to be well protected from a chronic complement activation due to higher levels of expression of cell surface complement regulators on syncytiotrophoblast cells. 26, 27 In pre-eclampsia, this normal protection appears to be compromised as loss of function mutations in surface regulators such as CD46 have been shown to be associated with preeclampsia. 28 Our data showing significantly increased MAC levels on placentas obtained from pre-eclampsia patients are consistent with these reports.
Exposure of human cytotrophoblast cells in vitro to low oxygen levels (hypoxia) induces upregulation and secretion of sFLT1. 29, 30 These in vitro findings were extrapolated to in vivo condition leading to the presumption that hypoxia is the primary driver of antiangiogenic F I G U R E 3 Complement activation stimulated the release of sFLT1 depending on degree of activation. A, Representative Western blot showing decreased levels of three sFLT1 isoforms with increasing degree of complement activation. B, The 100 Kd sFLT1 isoform band was quantified by density measurement. C, Levels of sFLT1 in cell culture media measured by ELISA. n = 3-5. *P = 0.015, **P = 0.03, ***P = 0.0003, ****P < 0.0001 milieu. However, role of hypoxia in the pathogenesis of pre-eclampsia is unclear. 31 Exposure of pregnant rodents to hypoxia increased the invasion of trophoblast cells in to maternal uterine spiral arteries. 32 Contrary to this, reduced trophoblast invasion and the subsequent defective uterine spiral artery remodeling have been consistently postulated to be central to pre-eclampsia pathogenesis. 33, 34 Although oxygen tension in first trimester human placenta is low (hypoxic), it is now well accepted as normal physiological state which is required for normal placental development. 35 In vivo studies relating placental hypoxia to antiangiogenic milieu and eventually pre-eclampsia heavily rely on increased expression of hypoxia response element HIF1α.
Recent data suggest that HIF1α was also reactive to autoantibodies such as anti-angiotensin II type I receptor and various stressors through stress kinases. 35, 36 Further, HIF1α could modulate angiogenic factors independent of oxygen levels. 35 Nevertheless, immunological factors may be upstream to the development of placental hypoxia. The most intriguing question is how an arm of immune system that was evolutionarily designed and conserved to kill foreign cells brane. 17 The physical removal of MAC occurs by both endocytosis and exocytosis. 52 It is possible that sFLT1 in trophoblast cells was secreted out as part of endo and/or exocytosis process of MAC removal. Our data indicating a good correlation between MAC levels and secreted sFLT1 levels are consistent with this hypothesis. The effect of complement activation on sFLT1 secretion in vivo could be more robust than our in vitro studies as the Ca 2+ levels used in our assays were limited. The removal of MAC from cell surface has been shown to be mediated by PKC activation and subsequent Ca 2+ influx. Further, rate of elimination of MAC was governed by extracellular Ca 2+ concentrations. 44 The Ca 2+ concentrations in the media used in our assays (0.15 mmol/L) were substantially lower than the circulating levels of (Ca 
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